Skip to content

Clinical research on treating sjogren’s syndrome by acupuncture combined with Traditional Chinese Medicine

Clinical research on treating sjogren’s syndrome by acupuncture combined with Traditional Chinese Medicine

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075208
Enrollment
Unknown
Registered
2023-08-29
Start date
2022-02-15
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary Sjogren syndrome

Interventions

Treatment group:Jiedu Tongluo Huashi Decoction+HCQ
Control group:The placebo+HCQ

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: -Age = 18 years old and = 70 years old, regardless of gender -In line with the 2002 European and American Collegiate classification standard of Sjogren syndrome -TCM diagnosis and syndrome differentiation conform to the diagnosis and classification standard of Xerosis (damp-heat syndrome) of "Shanghai Routine diagnosis and Treatment of TCM Diseases and Syndromes" -Within 8 weeks of baseline, only alternative therapy was received, have not received glucocorticoid and immunosuppressive therapy -Understand and agree to participate in this study and sign informed consent

Exclusion criteria

Exclusion criteria: -Combined with other connective tissue diseases -Ophthalmic contraindications for the combination of hydroxychloroquine, such as visual field defects and macular degeneration during fundus examination -Lesions in other organ involvement involving -Combined with cardiac conduction block (PR more than at least 0.2 sec and QRS more than at least 0.08 sec) -Combined with cardiovascular, cerebrovascular, liver, kidney and hematopoietic system severe primary diseases -Allergy and allergic to many medicines -Pregnancy or prepare for pregnancy, and lactation woman -Participants in or currently participating in other clinical trials within 1 month prior to enrollment -AIDS, lymphoma, sarcoidosis, hepatitis C virus infection

Design outcomes

Primary

MeasureTime frame
Change in ESSPRI relative to baseline at week 12;

Secondary

MeasureTime frame
ESSDAI;The secretion of saliva flow without stimulating;Schirmer's test;Corneal fluorescein staining;Breakup time of tear film;ESR;Complement;Immune globulin;RF;Changes in subjective indicators of dry mouth and dry eyes relative to baseline at weeks 4, 8, and 12;Autoimmune-related antibodies;

Countries

China

Contacts

Public ContactBen Li

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

cherrycheek_lb@126.com+86 137 6105 8125

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026